PRODAPT
14.2.2024 11:12:30 CET | Business Wire | Press release
Prodapt, the largest and fastest growing specialized company focused on the Connectedness industry, today announced the appointment of senior industry leader Manish Vyas to the Board as Executive Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213734047/en/
Manish Vyas, Executive Director and Board Member, Prodapt (Photo: Business Wire)
With an impressive 23-year tenure at Tech Mahindra, Manish Vyas left an indelible mark as President of the Communications, Media, and Entertainment (CME) business, alongside leadership roles as CEO of Network Services and BPO business units. In addition, as COO for strategic businesses like Experience Design & Digital Engineering, Manish mentored & provided strategic guidance to drive industry-leading growth. His visionary leadership was instrumental in Tech Mahindra's exponential revenue growth from $150 million to an approximately $6.5 billion powerhouse. Notably, he was pivotal in scaling the Communications & Media business significantly, achieving remarkable revenue and EBITDA milestones.
At Prodapt, Manish will guide the leadership team to drive strategic initiatives, reinforcing Prodapt’s position at the forefront of the industry and propelling its growth trajectory even further. With a comprehensive background spanning IT, business process, network services, systems integration, consulting, and large deal outsourcing, Manish brings a wealth of experience in delivering innovative solutions to achieve critical client objectives.
“I am thrilled to have Manish join the Prodapt team. With his exceptional track record as a visionary leader, Manish brings strategic thinking and innovative solutions that have successfully guided numerous global Communications Service Providers and large technology companies through their digital transformations. His joining Prodapt comes at a pivotal moment as we march towards our plans of achieving $1 billion in revenues,” Vedant Jhaver, Founder and Chairman of Prodapt, said.
“I'm energized to join the Prodapt Board and leadership team, where I get to do what I enjoy the most: solve customer problems at scale through innovation and technology. At Prodapt, we'll disrupt the status quo by leveraging AI & emerging tech while prioritizing our people and our planet. I fully share Vedant's vision of making Prodapt a globally recognized tech powerhouse, solving meaningful problems with cutting-edge solutions. This journey excites me immensely, and I'm ready to contribute my experience and passion to make Prodapt's future even brighter,” Manish Vyas said.
Welcoming Manish to Prodapt, CEO Harsha Kumar said: “Manish's industry expertise and people-centric approach are synergistic with that of our leadership team, and align perfectly with our mission and values. I'm very excited to partner with him on our next growth chapters.”
Vyas holds an impressive academic pedigree, including a Management degree from the renowned Narsee Monjee Institute of Management Studies Mumbai, India, Electronics Engineering from RCOEM Nagpur, India, and executive education from leading institutions like the Harvard Business School, Massachusetts Institute of Technology (MIT), and Yale University.
About Prodapt
Prodapt is the largest and fastest-growing specialized player in the Connectedness industry, recognized by Gartner as a Large, Telecom-Native Regional services provider across North America, Europe, and Latin America. With its singular focus on the domain, Prodapt has built deep expertise in the most transformative technologies that connect our world.
Prodapt is a trusted partner for enterprises across all layers of the Connectedness vertical. We design, configure, and operate solutions across their digital landscape, network infrastructure, and business operations – and craft experiences that delight their customers.
Today, our clients connect 1.1 billion people and 5.4 billion devices, and are among the largest telecom, media, and internet firms in the world. Prodapt works with Google, Amazon, Verizon, Vodafone, Liberty Global, Liberty Latin America, Claro, Lumen, Windstream, Rogers, Telus, KPN, Virgin Media, British Telecom, Deutsche Telekom, Cisco, Adtran, Samsung, and many more.
Prodapt employs over 6,000 technology and domain experts in 30+ countries across North America, Latin America, Europe, Africa, and Asia. Prodapt is part of the 130-year-old business conglomerate The Jhaver Group, which employs over 30,000 people across 80+ locations globally.
Visit www.prodapt.com for more information. Follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213734047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom